Skip to main content
Figure 3 | BMC Neurology

Figure 3

From: Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study

Figure 3

Association between cardiotoxicity risk and cumulative dose. Cardiac events includes patients with reported cardiac SAEs, with signs or symptoms of CHF requiring hospitalization or other therapy, with an LVEF decrease to 50% of baseline, or with a clinically significant drop in LVEF as indicated by a 10% decrease from baseline. CHF=congestive heart failure; LVEF=left ventricular ejection fraction; SAE=serious adverse event.

Back to article page